Armata Pharmaceuticals Inc 2026年季度报告

QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________Commission file number: 001-37544ARMATA PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter) Not Applicable (Former name, former address, and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was requiredto file such reports), and (2)has been subject to such filing requirements for the past 90days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company or an emerging growth company as defined in Rule12b-2 of the Exchange Act. See thedefinitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” inRule12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section13(a)of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). The number of shares of the registrant’s Common Stock, par value $0.01 per share, outstanding as of May 8, 2026 was36,710,810. TABLE OF CONTENTS PARTI. FINANCIAL INFORMATION Item1.Financial Statements (unaudited)6Condensed Consolidated Balance Sheets6Condensed Consolidated Statements of Operations7Condensed Consolidated Statements of Stockholders’ Deficit8Condensed Consolidated Statements of Cash Flows9Notesto Condensed Consolidated Financial Statements10Item2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations24Item3.Quantitative and Qualitative Disclosures About Market Risk38Item4.Controls and Procedures38PARTII. OTHER INFORMATION38Item1.Legal Proceedings38Item1A.Risk Factors38Item2.Unregistered Sales of Equity Securities and Use of Proceeds38Item3.Defaults upon Senior Securities38Item4.Mine Safety Disclosures39Item5.Other Information39Item6.Exhibits39SIGNATURES42 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) and certain information incorporatedherein by reference contain forward-looking statements, which are provided under the “safe harbor”protection of the Private Securities Litigation Reform Act of 1995. These statements relate to future events,results or to our future financial performance and involve known and unknown risks, uncertainties, andother factors which may cause our actual results, performance, or events to be materially different fromany future results, performance, or events expressed or implied by the forward-looking statements.Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding: ●our estimates regarding anticipated operating losses, capital requirements and needs foradditional funds;●our ability to raise additional capital when needed and to continue as a going concern;●our expected financial and operating performance;●our ability to manufacture, or otherwise secure the manufacture of, sufficient amounts of ourproduct candidates for our preclinical studies and clinical trials;●our clinical development plans, including planned clinical trials;●our research and development plans;●our ability to select combinations of phages to formulate our product candidates;●our development of bacteriophage-based therapies;●the potential use of bacteriophages to treat bacterial infections;●the potential future of antibiotic resistance;●the ability for bacteriophage therapies to disrupt and destroy biofilms and restore sensitivityto antibiotics;●the potential for bacteriophage technology being uniquely positioned to address the globalthreat of antibiotic resistance;●our planned development strategy, presenting data to regulatory agencies and definingplanned clinical studies;●the expected timing of additional clinical trials, including Phase 1, Phase 2, Phase 2b, Phase3 or registrational clinical trials;●our ability to manufacture and secure sufficient quantities of our product candidates forclinical trials;●the